Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
5 min read
Exploring rituximab-pvvr's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
25 October 2023
This article summarized the latest R&D progress of rituximab-pvvr, the Mechanism of Action for rituximab-pvvr, and the drug target R&D trends for rituximab-pvvr.
Valuable Targets
6 min read
Advances in Clinical Research on Nrf2 Inhibitor
25 October 2023
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a type of basic region-leucine zipper (bZIP) transcription factors, encoded by the NFE2L2 gene.
Drug Insights
4 min read
Decoding ruxolitinib phosphate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
25 October 2023
This article summarized the latest R&D progress of ruxolitinib phosphate, the Mechanism of Action for ruxolitinib phosphate, and the drug target R&D trends for ruxolitinib phosphate.
Latest Hotspot
3 min read
The latest data on Sunvozertinib, an EGFR inhibitor from Dizal Pharmaceutical, made its debut at the 2023 ESMO Conference
25 October 2023
Dizal Pharmaceutical'S EGFR inhibitor named Sunvozertinib for first-line treatment of EGFR exon20ins mutation type advanced NSCLC, debuted at the 2023 European Society for Medical Oncology (ESMO) meeting.
Drug Insights
5 min read
Deep Scientific Insights on salmeterol xinafoate's R&D Progress
25 October 2023
This article summarized the latest R&D progress of salmeterol xinafoate, the Mechanism of Action for salmeterol xinafoate, and the drug target R&D trends for salmeterol xinafoate.
Valuable Targets
4 min read
Analysis on the Clinical Research Progress of Nitric Oxide Synthase
25 October 2023
Nitric oxide synthase (NOS) is an essential enzyme in the human body that plays a crucial role in various physiological processes.
Drug Insights
5 min read
An In-depth Analysis of serplulimab's R&D Progress and Mechanism of Action on Drug Target
25 October 2023
This article summarized the latest R&D progress of serplulimab, the Mechanism of Action for serplulimab, and the drug target R&D trends for serplulimab.
Latest Hotspot
3 min read
amgen-announces-phase-iii-study-data-for-kras-g12c-inhibitor-sotorasib
25 October 2023
On Oct 22, 2023, Amgen published results from their CodeBreaK 300 study on Lumakras and Vectibix's efficacy in treating chemo-resistant mCRC with KRAS G12C mutation.
Feature Updates
5 min read
Easily gain insights into global drug trade intelligence with the Synapse database!
24 October 2023
The Synapse database launches a drug transaction library to assist users in the BD and strategy departments of pharmaceutical companies in gaining insights into global drug transaction intelligence.
Valuable Targets
4 min read
Advances in Clinical Research on NMDA Receptor Agonist
24 October 2023
The NMDA receptor (N-methyl-D-aspartic acid receptor) is a subtype of the ionotropic glutamate receptor, with a complex molecular structure and unique pharmacological properties.
Drug Insights
5 min read
Strontium ranelate: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
24 October 2023
This article summarized the latest R&D progress of strontium ranelate, the Mechanism of Action for strontium ranelate, and the drug target R&D trends for strontium ranelate.
Latest Hotspot
3 min read
Shanghai Huaota Biopharmaceutical's IL-36R monoclonal antibody, HB0034, has been granted Orphan Drug Designation by the FDA for the treatment of generalized pustular psoriasis
24 October 2023
Shanghai Huaota Biopharmaceutical's HB0034 anti-IL-36R monoclonal antibody injection was granted orphan drug designation by the U.S. FDA for the treatment of generalized pustular psoriasis (GPP).